ABSTRACT

We aimed to evaluate the capacity of measuring serum anti-mullerian hormone (AMH) levels in determining ovarian reserve in patients with polycystic ovary syndrome (PCOS) with increased ovarian reserve and in premenopausal women with decreased ovarian reserve.

Seventy-five patients who presented to our clinic between May-September 2011 were included. The patients comprised 25 (20-35 years) with PCOS, 25 (20-35 years) with normo-ovulatory cycle, and 25 (40-45 years) in the premenopausal period. Blood specimen was taken from patients during the early follicular period (on the third day of spontaneous menstrual cycles) and FSH, LH, estradiol (E2), and AMH levels were analyzed. In addition, body mass indexes (BMI) of the patients were calculated by measuring their heights and weights.

We determined statistically significant differences between groups regarding AMH values (p<0.001). We determined the mean AMH value of the PCOS group to be 58.45±33.68 pmol/L, 19.92±21.35 pmol/L for the control group, and 2.47±5.31 pmol/L for the premenopausal group. We found a statistically significant negative relationship between AMH and BMI levels in all cases without discrimination (r:-0,277; p=0.016), and we found a statistically significant positive relationship between AMH and AFC (antral follicle count) (r: 0.908; p=<0.001).

AMH is a highly specific biomarker in determining ovarian reserve. High levels of AMH values in patients with PCOS and low levels in premenopausal women demonstrate that AMH is a safe biomarker in determining ovarian reserve. (JAREM 2014; 2: 62-8)